These findings suggest that inhibiting ROR1 may be an attractive approach to treating human cancers including those exhibiting EGFR–TKI resistance due to bypass signalling through other non-targeted RTKs such as MET and IGF-IR. This evidence concerns the gene EGFR and cancer.